Tenax Therapeutics Inc (TENX)
3.10
-0.04
(-1.27%)
USD |
NASDAQ |
Jun 17, 16:00
3.10
0.00 (0.00%)
After-Hours: 20:00
Tenax Therapeutics Enterprise Value: -6.066M for June 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 17, 2024 | -6.066M |
| June 14, 2024 | -5.988M |
| June 13, 2024 | -5.870M |
| June 12, 2024 | -5.713M |
| June 11, 2024 | -5.439M |
| June 10, 2024 | -5.420M |
| June 07, 2024 | -5.380M |
| June 06, 2024 | -5.224M |
| June 05, 2024 | -5.126M |
| June 04, 2024 | -5.341M |
| June 03, 2024 | -5.263M |
| May 31, 2024 | -5.361M |
| May 30, 2024 | -5.283M |
| May 29, 2024 | -5.214M |
| May 28, 2024 | -5.283M |
| May 24, 2024 | -5.263M |
| May 23, 2024 | -5.165M |
| May 22, 2024 | -5.048M |
| May 21, 2024 | -4.950M |
| May 20, 2024 | -4.754M |
| May 17, 2024 | -5.187M |
| May 16, 2024 | -5.185M |
| May 15, 2024 | -5.106M |
| May 14, 2024 | -5.341M |
| May 13, 2024 | -5.185M |
| Date | Value |
|---|---|
| May 10, 2024 | -5.116M |
| May 09, 2024 | -5.146M |
| May 08, 2024 | -5.185M |
| May 07, 2024 | -5.224M |
| May 06, 2024 | -4.871M |
| May 03, 2024 | -4.617M |
| May 02, 2024 | -4.715M |
| May 01, 2024 | -4.499M |
| April 30, 2024 | -4.499M |
| April 29, 2024 | -4.950M |
| April 26, 2024 | -5.322M |
| April 25, 2024 | -5.087M |
| April 24, 2024 | -5.165M |
| April 23, 2024 | -5.283M |
| April 22, 2024 | -5.165M |
| April 19, 2024 | -5.028M |
| April 18, 2024 | -4.930M |
| April 17, 2024 | -5.106M |
| April 16, 2024 | -5.067M |
| April 15, 2024 | -5.077M |
| April 12, 2024 | -4.774M |
| April 11, 2024 | -4.558M |
| April 10, 2024 | -4.558M |
| April 09, 2024 | -4.46M |
| April 08, 2024 | -4.362M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-8.239M
Minimum
Jun 16 2023
52.33M
Maximum
Jun 28 2021
7.724M
Average
2.597M
Median
Feb 11 2020
Enterprise Value Benchmarks
| CEL-SCI Corp | 62.39M |
| AIM ImmunoTech Inc | 14.12M |
| IGC Pharma Inc | 25.11M |
| NovaBay Pharmaceuticals Inc | 3.447M |
| Protalix BioTherapeutics Inc | 53.31M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.799M |
| Total Expenses (Quarterly) | 3.908M |
| EPS Diluted (Quarterly) | -3.12 |
| Earnings Yield | -818.1% |